Greenwich LifeSciences, Inc.
GLSI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $146,154 | $135,163 | $196,290 | $314,931 |
| - Cash | $4,092 | $6,989 | $13,468 | $27,204 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $142,062 | $128,173 | $182,822 | $287,727 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$4 | -$4 | -$4 | -$4 |
| % Margin | – | – | – | – |
| EBITDA | -$15,785 | -$9,324 | -$8,037 | -$4,594 |
| % Margin | – | – | – | – |
| Net Income | -$15,789 | -$8,892 | -$7,825 | -$4,571 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.21 | -0.69 | -0.61 | -0.35 |
| % Growth | -75.4% | -13.1% | -74.3% | – |
| Operating Cash Flow | -$7,267 | -$6,479 | -$6,200 | -$4,292 |
| Capital Expenditures | $0 | $0 | -$0 | $0 |
| Free Cash Flow | -$7,267 | -$6,479 | -$6,200 | -$4,292 |